Show simple item record

Polatuzumab Vedotin + Obinutuzumab + Venetoclax In Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (Fl): Primary Analysis Of A Phase 1b/2 Trial

dc.contributor.authorBannerji, R.
dc.contributor.authorYuen, S.
dc.contributor.authorPhillips, T.
dc.contributor.authorArthur, C.
dc.contributor.authorIsufi, I.
dc.contributor.authorMarlton, P.
dc.contributor.authorSeymour, J. F.
dc.contributor.authorCorradini, P.
dc.contributor.authorMolinari, A.
dc.contributor.authorGritti, G.
dc.contributor.authorEmmons, R.
dc.contributor.authorHirata, J.
dc.contributor.authorMusick, L.
dc.contributor.authorSaha, S.
dc.contributor.authorCroft, B.
dc.contributor.authorFlowers, C.
dc.date.accessioned2021-07-01T20:11:03Z
dc.date.available2022-07-01 16:11:02en
dc.date.available2021-07-01T20:11:03Z
dc.date.issued2021-06
dc.identifier.citationBannerji, R.; Yuen, S.; Phillips, T.; Arthur, C.; Isufi, I.; Marlton, P.; Seymour, J. F.; Corradini, P.; Molinari, A.; Gritti, G.; Emmons, R.; Hirata, J.; Musick, L.; Saha, S.; Croft, B.; Flowers, C. (2021). "Polatuzumab Vedotin + Obinutuzumab + Venetoclax In Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (Fl): Primary Analysis Of A Phase 1b/2 Trial." Hematological Oncology 39: n/a-n/a.
dc.identifier.issn0278-0232
dc.identifier.issn1099-1069
dc.identifier.urihttps://hdl.handle.net/2027.42/168282
dc.publisherWiley Periodicals, Inc.
dc.titlePolatuzumab Vedotin + Obinutuzumab + Venetoclax In Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (Fl): Primary Analysis Of A Phase 1b/2 Trial
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelOtolaryngology
dc.subject.hlbsecondlevelNeurosciences
dc.subject.hlbsecondlevelObstetrics and Gynecology
dc.subject.hlbsecondlevelOncology and Hematology
dc.subject.hlbsecondlevelOphthalmology
dc.subject.hlbsecondlevelPublic Health
dc.subject.hlbsecondlevelInternal Medicine and Specialties
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/168282/1/hon23_2880.pdf
dc.identifier.doi10.1002/hon.23_2880
dc.identifier.sourceHematological Oncology
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.